Differences in drug treatment of chronic heart failure between European countries

European Heart Journal

Volumn 20, Issue 9, 1999, Pages 666-672

  Van Veldhuisen, D J ^a   Charlesworth, A ^c   Crijns, H J G M ^a   Lie, K I ^b   Hampton, J R ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Heart failure; International differences; Treatment

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; LISINOPRIL; NITRATE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DRUG COST; EUROPE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; EUROPE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES;

EID: 0032932870     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1343     Document Type: Article

References (24)

1. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. Arch Intern Med. 156:1996;1669-1673.
2. Bourassa MG, Gurné O, Bangdiwala SI. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 22 (Suppl A):1993;14A-9A.
3. Pitt B, Nicklas JM. Target doses of ACE inhibitors in heart failure: where should we aim. Eur Heart J. 19:1998;370-371.
4. Packer M, Poole-Wilson P, Armstrong P. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival study (ATLAS)(abstract). Eur Heart J. 19 (Abstr Suppl):1998;142.
5. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 19:1998;481-489.
6. Szabó BM, Van Veldhuisen DJ, De Graeff PA, Lie KI. Alterations in the prognosis of chronic heart failure: An overview of the major mortality trials. Cardiovasc Drugs Ther. 11:1997;427-434.
7. Packer M. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. Eur Heart J. 19 (Suppl B):1998;B40-B46.
8. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 12:1997;276-287.
9. Holmes DR, Califf RM, van de Werf F. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO Trial. Lancet. 349:1997;75-78.
10. Hampton JR, Van Veldhuisen DJ, Kleber FX. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 349:1997;971-977.
11. Williams JF, Bristow MR, Fowler MB. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 26:1995;1376-1398.
12. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 18:1997;736-753.
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
14. Smith TW. Digoxin in heart failure. N Engl J Med. 329:1993;51-53.
15. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and on congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 350:1997;1417-1424.
16. Massie BM, Cleland JGF, Armstrong PW. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. J Card Fail. 4:1998;3-8.
17. Stevenson WG, Stevenson LW, Middlekauff HR. Improving survival of patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 26:1995;1417-1423.
18. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
19. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 31:1998;749-753.
20. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) Trial. J Am Coll Cardiol. 31:1998;419-425.
21. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 97:1998;1231-1233.
22. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol. 30:1997;518-526.
23. Reis SE, Holubkov R, Edmundowicz D. Treatment of patients admitted to the hospital with congestive heart failure: speciality-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 30:1997;733-738.
24. Bart B, Ertl G, Maggioni AP. Contemporary management of patients with left ventricular dysfunction: preliminary results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry (abstr). Eur Heart J. 18 (Abstr Suppl):1997;402.